CymaBay Therapeutics Inc (CBAY) CEO Sujal Shah Purchases 5,000 Shares
CymaBay Therapeutics Inc (NASDAQ:CBAY) CEO Sujal Shah acquired 5,000 shares of CymaBay Therapeutics stock in a transaction on Monday, October 15th. The shares were bought at an average cost of $9.90 per share, for a total transaction of $49,500.00. Following the completion of the transaction, the chief executive officer now owns 100,000 shares in the company, valued at approximately $990,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Sujal Shah also recently made the following trade(s):
- On Friday, July 27th, Sujal Shah acquired 5,000 shares of CymaBay Therapeutics stock. The shares were bought at an average cost of $10.90 per share, for a total transaction of $54,500.00.
NASDAQ:CBAY opened at $10.12 on Tuesday. The stock has a market capitalization of $654.30 million, a PE ratio of -12.81 and a beta of 2.01. CymaBay Therapeutics Inc has a 1-year low of $7.63 and a 1-year high of $15.59.
Several large investors have recently added to or reduced their stakes in CBAY. LPL Financial LLC purchased a new stake in shares of CymaBay Therapeutics in the 1st quarter worth about $130,000. Legal & General Group Plc purchased a new stake in shares of CymaBay Therapeutics in the 2nd quarter worth about $134,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of CymaBay Therapeutics in the 2nd quarter worth about $145,000. Teacher Retirement System of Texas purchased a new stake in shares of CymaBay Therapeutics in the 2nd quarter worth about $151,000. Finally, PNC Financial Services Group Inc. purchased a new stake in CymaBay Therapeutics during the 2nd quarter valued at about $152,000. 95.48% of the stock is currently owned by hedge funds and other institutional investors.
A number of research analysts have issued reports on the stock. Zacks Investment Research downgraded shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, July 10th. Raymond James assumed coverage on shares of CymaBay Therapeutics in a research report on Thursday, June 28th. They set an “outperform” rating and a $20.00 price objective on the stock. BidaskClub downgraded shares of CymaBay Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 17th. Piper Jaffray Companies upped their target price on shares of CymaBay Therapeutics to $30.00 and gave the stock an “overweight” rating in a research report on Friday, August 10th. Finally, Oppenheimer set a $20.00 target price on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research report on Thursday, August 9th. Two research analysts have rated the stock with a sell rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $21.88.
CymaBay Therapeutics Company Profile
CymaBay Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar, a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase II clinical study for the treatment of primary biliary cholangitis, as well as patients with nonalcoholic steatohepatitis.
Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.